Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
作者： Claus Garbe , Thomas K. Eigentler , Ulrich Keilholz , Axel Hauschild , John M. Kirkwood
DOI: 10.1634/THEONCOLOGIST.2010-0190
关键词:
摘要: … treatments for advanced, metastatic disease was conducted to present the success of current treatments … incremental improvements in the treatment of advanced, metastatic melanoma. …
geomar.de
oup.com
alphamedpress.org 参考文章(110)
B. Redman, T. F. Gajewski, D. Pavlov, C. Bulanhagui, A. Ribas, L. H. Camacho, J. Gomez-Navarro, S. Antonia, J. Sosman, J. M. Kirkwood, Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study Journal of Clinical Oncology. ,vol. 25, pp. 8524- 8524 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.8524
G.J. Stoter, C. Scheibenbogen, F.J. Lejeune, U. Keilholz, A.M.M. Eggermont, C.J.A. Punt, Recombinant interleukin-2 based treatments for advanced melanoma: The experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group The cancer journal from Scientific American. ,vol. 3, ,(1997)
Vanna Chiarion-Sileni, Paola Del Bianco, Antonella Romanini, Michele Guida, Adriano Paccagnella, Maurizio Dalla Palma, Emanuele Naglieri, Ruggero Ridolfi, Barbara Silvestri, Maria Michiara, Gian Luca De Salvo, Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874] BMC Cancer. ,vol. 6, pp. 44- 44 ,(2006) , 10.1186/1471-2407-6-44
J. S. Weber, E. M. Hersh, M. Yellin, G. M. Nichol, W. Urba, J. D. Powderly, S. J. O’Day, The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma Journal of Clinical Oncology. ,vol. 25, pp. 8523- 8523 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.8523
R. Kefford, H. Arkenau, M. P. Brown, M. Millward, J. R. Infante, G. V. Long, D. Ouellet, M. Curtis, P. F. Lebowitz, G. S. Falchook, Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Journal of Clinical Oncology. ,vol. 28, pp. 8503- 8503 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.8503
Leslie A. Fecher, Keith T. Flaherty, Where are we with adjuvant therapy of stage III and IV melanoma in 2009 Journal of The National Comprehensive Cancer Network. ,vol. 7, pp. 295- 304 ,(2009) , 10.6004/JNCCN.2009.0022
J M Kirkwood, M H Strawderman, M S Ernstoff, T J Smith, E C Borden, R H Blum, Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. Journal of Clinical Oncology. ,vol. 14, pp. 7- 17 ,(1996) , 10.1200/JCO.1996.14.1.7
D R Parkinson, J S Abrams, P H Wiernik, A A Rayner, K A Margolin, D A Van Echo, M Sznol, J P Dutcher, F R Aronson, J H Doroshow, Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. Journal of Clinical Oncology. ,vol. 8, pp. 1650- 1656 ,(1990) , 10.1200/JCO.1990.8.10.1650
John M. Kirkwood, Joseph G. Ibrahim, Vernon K. Sondak, Jon Richards, Lawrence E. Flaherty, Marc S. Ernstoff, Thomas J. Smith, Uma Rao, Mary Steele, Ronald H. Blum, High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190 Journal of Clinical Oncology. ,vol. 18, pp. 2444- 2458 ,(2000) , 10.1200/JCO.2000.18.12.2444
H Pehamberger, H P Soyer, A Steiner, R Kofler, M Binder, P Mischer, W Pachinger, J Auböck, P Fritsch, H Kerl, K Wolff, Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. Journal of Clinical Oncology. ,vol. 16, pp. 1425- 1429 ,(1998) , 10.1200/JCO.1998.16.4.1425